[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354066-105":59,"doc-detail-354066-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","characterizing-the-effects-of-anti-pd1-immunotherapy-on-ataxia-in-a-vestibular-schwannoma-mouse-model","Characterizing the effects of anti-PD1 immunotherapy on ataxia in a vestibular schwannoma mouse model","","Vestibular schwannoma is a non-malignant tumor that can cause hearing loss, facial paralysis, vestibular dysfunction, severe ataxia, and impaired mobility, with gait disturbances and fall risk. Although immune checkpoint inhibitors have transformed cancer care, their role in non-malignant tumors remains unclear due to immune-related adverse events such as neuroinflammation and brain edema. This study evaluates anti-PD1 treatment effects on neurological symptoms in a mouse model and tests strategies to mitigate toxicity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/characterizing-the-effects-of-anti-pd1-immunotherapy-on-ataxia-in-a-vestibular-schwannoma-mouse-model/354066/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/characterizing-the-effects-of-anti-pd1-immunotherapy-on-ataxia-in-a-vestibular-schwannoma-mouse-model/354066.png","ImageObject",300,407,{"name":92,"@type":93},"Fahsai","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s primary goal regarding anti-PD1 therapy?","Question",{"text":112,"@type":113},"To evaluate how anti-PD1 treatment affects neurological symptoms, specifically ataxia, in a vestibular schwannoma mouse model.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What effects did anti-PD1 (αPD1) have in the mice?",{"text":117,"@type":113},"αPD1 alleviated ataxia but also triggered a systemic immune response that led to brain edema and inflammation.",{"name":119,"@type":110,"acceptedAnswer":120},"Why was anti-VEGF (αVEGF) combined with αPD1, and what was the outcome?",{"text":121,"@type":113},"αVEGF was chosen to normalize tumor vasculature and reduce vasogenic edema, potentially improving neurological function. Combined αPD1 and αVEGF therapy significantly improved ataxia and inhibited inflammatory AKT and JAK2/STAT3 signaling activation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354066,1790458564,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","Journal of Neuro-Oncology (2026) 177:120  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1060-026-05574-8  \nRESEARCH  \nCharacterizing the effects of anti-PD1 immunotherapy on ataxia in a vestibular schwannoma mouse model  \nSimeng Lu1 · Miriam Hernandez-Meadows1,2,3 · Zhenzhen Yin1 · Bingyu Xiu1 · Adam P. Jones1 · D. Bradley Welling4 · Lei Xu1  \nReceived: 10 April 2025 / Accepted: 12 April 2026 / Published online: 24 April 2026 © The Author(s) 2026  \nAbstract  \nPurpose Vestibular schwannoma (VS) is a non-malignant tumor arising from Schwann cells of the vestibulocochlear nerve. While not malignant, VS can significantly impact patients’ quality of life by causing hearing loss, facial paralysis, vestibular dysfunction, and impaired mobility. The resulting ataxia is particularly debilitating, often resulting in significant gait disturbances and an increased risk of falls. Current treatment options, including surgery and radiotherapy, carry risks of further damaging the surrounding cranial nerves, underscoring the need for more effective and less invasive therapeutic strategies. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet their potential in non-malignant tumors like VS remains unexplored. Immune-related adverse events, particularly neurological complications such as neuroinflammation and brain edema, pose challenges for their application in VS. In this study, we aimed to evaluate the effects of anti-PD1 (αPD1) treatment on neurological symptoms.  \nMethods In the cerebellopontine angle model of VS that reproduces schwannoma-induced ataxia, we used a panel of tests to evaluate the efficacy of αPD1 monotherapy and combination therapy with anti-VEGF (αVEGF) on alleviating ataxia. Results Our results demonstrated that αPD1 treatment alleviated ataxia in mice but also triggered a systemic immune response, leading to brain edema and inflammation. To mitigate these adverse effects and optimize αPD1 therapy, we investigated combination strategies. αVEGF treatment, known for its ability to normalize tumor vasculature, can reduce vasogenic edema of the brain and peripheral nerve and improve neurological function in VS models. Here, we demonstrated that combined αPD1 and αVEGF therapy significantly improved ataxia and inhibited the activation of the inflammatory AKT and JAK2/STAT3 signaling pathways (n=18 mice/arm in animal studies) .  \nConclusion These findings suggest that a combinatorial approach using αVEGF and αPD1 may reduce immunotherapyinduced neuroinflammation and neurotoxicity, offering a promising therapeutic strategy for VS management.  \nKeywords Vestibular schwannoma · Combined anti-VEGF and immunotherapy · Ataxia  \nSimeng Lu and Miriam Hernandez-Meadows contributed equally to this work.  \n􀀍 Lei Xu [lexu@mgh.harvard.edu](lexu@mgh.harvard.edu)  \n1 Edwin Steele Laboratories of Tumor Biology, Department of Radiation Oncology, Cox-7, Massachusetts General Hospital, Boston, MA 02114, USA  \n2 Division of Immunology, Immunity to Infection and Respiratory Medicine, Faculty of Biology, Medicine & Health, The University of Manchester, Manchester M13 9PT, UK  \n3 Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust, The University of Manchester, Manchester M13 9PT, UK  \n4 Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA  \nIntroduction  \nNF2-related Schwannomatosis (NF2-SWN) is an autosomal dominant syndrome resulting from loss-of-function mutations in the NF2 tumor suppressor gene product, Merlin [1] . In NF2-SWN, schwannomas develop along the vestibulocochlear nerve, with bilateral vestibular schwannomas (VS) forming in greater than 95% of cases [2] . Though typically non-malignant, VS can disrupt vestibulocochlear nerve function, leading to hearing loss, severe ataxia, and other neurological deficits [3] .","cbCain3S1FjXACMn","https://ap.wps.com/l/cbCain3S1FjXACMn","pdf",3671578,13,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What is the study’s primary goal regarding anti-PD1 therapy?\",\"answer\":\"To evaluate how anti-PD1 treatment affects neurological symptoms, specifically ataxia, in a vestibular schwannoma mouse model.\"},{\"question\":\"What effects did anti-PD1 (αPD1) have in the mice?\",\"answer\":\"αPD1 alleviated ataxia but also triggered a systemic immune response that led to brain edema and inflammation.\"},{\"question\":\"Why was anti-VEGF (αVEGF) combined with αPD1, and what was the outcome?\",\"answer\":\"αVEGF was chosen to normalize tumor vasculature and reduce vasogenic edema, potentially improving neurological function. Combined αPD1 and αVEGF therapy significantly improved ataxia and inhibited inflammatory AKT and JAK2/STAT3 signaling activation.\"}]","Characterizing the effects of anti-PD1 immunotherapy on ataxia in a vestibular schwannoma mouse model | PDF",1790108683,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/156543a74df4d7767672b32b6ebe12f8.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/801c62115007637c0ea9e79eb3328144.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91d62c9a26394f7fd5422e12370f1c48.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07ac4a24ae47a253f963dc58f2c74071.webp",980,1301]